Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that the U.S. District Court for the District of Delaware reaffirmed an April 2010 federal jury decision that determined Medtronic CoreValve LLC willfully infringed Edwards' U.S. Andersen transcatheter heart valve patent and awarded Edwards $74 million in damages. The court also ruled that Edwards is entitled to recover additional damages due to continued infringing sales from the date of the trial through the life of the patent, plus interest.
In the same ruling, the court denied Edwards' motions for increased damages and a permanent injunction relating to Medtronic CoreValve's willful infringement. Edwards plans to appeal these rulings promptly.
About Edwards Lifesciences Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com (http://www.edwards.com) .
Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences and the stylized E logo trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.